中华临床免疫和变态反应杂志2017，Vol.11Issue(4)：322-326,5.DOI:10.3969/j.issn.1673-8705.2017.04.003
生物制剂联合甲氨蝶呤和柳氮磺胺吡啶治疗强直性脊柱炎伴髋关节炎的临床疗效
Efficacy of Biological Agents Combined with Methotrexate and Sulfasalazine for Ankylosing Spondylitis with Hip Joint Involvement
摘要
Abstract
Objective To evaluate the efficacy and safety of biological agent for ankylosing spondylitis with hip joint involvement .Methods 178 patients with confirmed AS complicated with hip joint involve-ment met the criteria for candidates receiving biological agents were divided into the control group ( n=52) and the observation group ( n=126) .The control group received oral methotrexate plus sulfasalazine while the observation group received oral methotrexate in combination with biological agent .The curative efficacy in the two groups after 24 weeks treatment , and the clinical and laboratory parameters as well as adverse drug reactions at 12 and 24 week were evaluated .Results After 24 weeks of treatment , the response rate of the observation group was significantly better than the control group ( P<0.01);after treatment of 12 and 24 weeks, the observation group showed significant better improvement in ASDAS , BASFI, Harris score, CRP, ESR, and other indicators, the differences were statistically significant (P<0.01).In the control group as compared with before treatment , the control group was significantly different in BASDAI , BASFI, CRP and ESR at week 24 ( P<0.05) .Comparative evaluation of the observation group and the thalidomide control group, the ASAS20 remission rate at week 24 was 51.7％vs.38.6％(P=0.135), and the ASAS40 remission rate was 40.0％vs.22.9％(P=0.035), the ASAS partial remission rate was 33.3％vs.12.8％(P=0.005).No significant adverse drug reactions were noted in either group .Conclusion Biological agent treatment of AS complicated with hip joint involvement may result in early induction and remission and it is safe and effective .关键词
脊柱炎,强直性/髋关节炎/生物制剂Key words
spondylitis,ankylosing/hip/biological agent分类
医药卫生引用本文复制引用
韩青,梁强,吴振彪,冷南,朱平..生物制剂联合甲氨蝶呤和柳氮磺胺吡啶治疗强直性脊柱炎伴髋关节炎的临床疗效[J].中华临床免疫和变态反应杂志,2017,11(4):322-326,5.基金项目
国家973计划课题(2015CB553704) （2015CB553704）
